Literature DB >> 10434917

Pneumomediastinum complicating bleomycin related lung damage.

T Sikdar1, D MacVicar, J E Husband.   

Abstract

We describe two patients who developed spontaneous pneumomediastinum without pneumothorax against a background of bleomycin-induced pulmonary interstitial disease whilst on treatment for metastatic germ cell tumours of the testis. Pneumomediastinum is a rare but recognized complication of bleomycin-induced lung toxicity, which has previously only been described in association with pneumothorax.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10434917     DOI: 10.1259/bjr.71.851.10434917

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  5 in total

1.  Extensive pneumothorax, pneumomediastinum and surgical emphysema as a complication of bleomycin therapy.

Authors:  Tarun P Jain; Sanjay Thulkar; Sanchita Saha; Sameer Bakhshi; Joseph Dominic
Journal:  Pediatr Radiol       Date:  2005-08-12

2.  Pneumothorax as an adverse drug event: an exploratory aggregate analysis of the US FDA AERS database including a confounding by indication analysis inspired by Cornfield's condition.

Authors:  Manfred Hauben; Eric Y Hung
Journal:  Int J Med Sci       Date:  2013-06-13       Impact factor: 3.738

3.  Pneumomediastinum, subcutaneous emphysema, and pneumothorax after a pulmonary function testing in a patient with bleomycin-induced interstitial pneumonitis.

Authors:  Mariana Sponholz Araujo; Frederico Leon Arrabal Fernandes; Fernando Uliana Kay; Carlos Roberto Ribeiro Carvalho
Journal:  J Bras Pneumol       Date:  2013 Sep-Oct       Impact factor: 2.624

4.  Spontaneous Pneumomediastinum and Bilateral Pneumothoraces in a Patient with Bleomycin-Induced Pneumonitis.

Authors:  Matthieu Barras; Marc Uhlmann
Journal:  Eur J Case Rep Intern Med       Date:  2017-10-09

5.  Thin-section CT assessment of spontaneous pneumomediastinum in interstitial lung disease: correlation with serial changes in lung parenchymal abnormalities.

Authors:  Shin Matsuoka; Yasuyuki Kurihara; Kunihiro Yagihashi; Kyoko Okamoto; Hiroshi Niimi; Yasuo Nakajima
Journal:  Respir Med       Date:  2005-06-02       Impact factor: 3.415

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.